Compliance, security and biotech to drive packaging

Freedonia Group says it expects regulatory and standards updates regarding barrier protection, patient compliance, and counterfeiting to drive demand for enhanced-barrier plastic bottles, calendar and wallet blister packaging, prefillable syringes and inhalers, track/trace and authentication labels and unit-dose pouches.

Prefillable syringes and vials, Freedonia expects, will lead growth in primary packaging thanks to new biotech products, which require injection. Plastic bottles, however, will still be the most widely used package for oral drugs distributed in bulk and prescription-dose volumes. Requirements for unit dose packaging, including expanded label content and built-in track and trace features, will drive blister packaging.

Child-resistant caps are expected to remain the top closures for oral and liquid drug containers, but will lose momentum as blister packs and pouches penetrate unit dose applications.

The market researcher forecasts a 5.5 percent annual rise in demand for these value-added containers through 2014, to $18.4 billion.

- see the release

Suggested Articles

The FDA has found issues with the testing practices of a U.S. generics maker that had specific problems with ADHD and weight-loss drugs.

A warning letter says Chinese API maker Yibin Lihao Bio-technical was found lying to the FDA about manufacturing unapproved heparin.

It took four tries over four years, but Perrigo has finally gotten FDA approval of its generic of Teva’s tricky-to-make ProAir HFA asthma inhaler.